C4 Therapeutics, Inc. (CCCC) Net margin 2021–2025
C4 Therapeutics, Inc. (CCCC) net profit margin by fiscal year — reported net income divided by reported revenue.
-292.1%FY2025 · since FY2021: -183.2% → -292.1%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -292.1% | +3.9 pp |
| FY2024 | -296.0% | +342.4 pp |
| FY2023 | -638.3% | -226.1 pp |
| FY2022 | -412.2% | -229.0 pp |
| FY2021 | -183.2% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More CCCC financial trends
CCCC RevenueCCCC Net incomeCCCC Gross profitCCCC Gross marginCCCC Operating incomeCCCC Operating marginCCCC Operating cash flowCCCC Free cash flowCCCC Capital expendituresCCCC Return on equityCCCC Stock buybacksCCCC Dividends paidCCCC Total assetsCCCC Total liabilitiesCCCC Shareholders’ equityCCCC overview →